Ambrose PG, Bhavnani SM, Andes DR, Bradley JS, Flamm RK, Pogue JM and Jones RN. Old in vitro antimicrobial breakpoints are misleading stewardship efforts, delaying adoption of innovative therapies, and harming patients. Open Forum Infect Dis. 7 (7): ofaa084, 2020.
Nguyen HM and Jones RN. Reanalysis of cefazolin surrogate susceptibility breakpoints utilized as guidances for oral cephalosporin treatments of uncomplicated urinary tract infections: caution concerning application to cefadroxil. Diagn Microbiol Infect Dis. 115053, 2020.
Pogue JM, Jones RN, Bradley JS, Andes DR, Bhavnani SM, Drusano GL, Dudley MN, Flamm RK, Rodvold KA and Ambrose PG. Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Antimicrob Agents Chemother. 64 (2), 2020.
Sader HS and Jones RN. Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centres (2015-2018). Clin. Microbiol. Infect. 26 (5): 658-659, 2020.
Flamm RK, Pfaller MA, Ambrose PG, Andes DR, Bradley JS, Bhavnani SM and Jones RN. Updated fluoroquinolone MIC breakpoints: Impact on susceptibility rates in the United States. ID Week, October 2-4, Washington, DC, Poster No. 1591, 2019.
Nguyen HM and Jones RN. Cephalexin and cefadroxil are not therapeutic equivalents for uncomplicated cystitis (uUTI): Further analysis of cefazolin surrogate susceptibility testing criteria. ID Week, October 2-6, Washington, DC, Poster No. 1453, 2019.
Pfaller MA, Flamm RK, Ambrose PG, Andes DR, Bradley JS, Bhavnani SM and Jones RN. Updated aminoglycoside MIC Breakpoints to minimize adverse events and improve outcome: Impact on susceptibility rates. ID Week, October 2-6, Washington, DC, Poster No. 1590, 2019.
Pogue JM, Jones RN, Bradley JS, Andes DR, Bhavnani SM, Dudley MN, Flamm RK, Rodvold KA and Ambrose PA. Polymyxin antimicrobial susceptibility testing and breakpoints for Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). ID Week, October 2-6. Washington, DC: Poster NO. 1534, 2019.
Bhavnani SM, Ambrose PG, Bradley JS, Dudley MN, Jones RN, Craig WA. Evaluation of Quinolone In Vitro Susceptibility Test Interpretive Criteria by USCAST. Poster No. A-475. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. September 17-21, 2015.
Bhavnani SM, Ambrose PG, Andes DR, Bradley JS, Craig WA, Drusano GL, Jones RN. Aminoglycoside Susceptibility Testing Breakpoint Re-Evaluations: Updates Based on the Application of Pharmacokinetics-Pharmacodynamics and Contemporary Microbiology Surveillance Data. Poster No. 1977. IDWeek 2016, New Orleans, LA. October 24-30, 2016.
Bhavnani SM, Onufrak NJ, Hammel JP, Andes DR, Bradley JS, Flamm RK, Ambrose PG, Jones RN. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics-Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data. Poster No. 2562. IDWeek 2018, San Francisco, CA. October 3-7, 2018.
Bhavnani SM, Ambrose PG, Andes DR, Bradley JS, Craig WA, Drusano GL and Jones RN. Aminoglycoside susceptibility testing breakpoint re-evaluations: Updates based on the application of pharmacokinetics-pharmacodynamics and contemporary microbiology surveillance data. ID Week, October 24-30, New Orleans, LA, Poster No. 1977, 2016.
Bhavnani SM, Ambrose PG, Bradley JS, Dudley MN, Jones RN and Craig WA. Evaluation of quinolone in vitro susceptibility test interpretive criteria by USCAST. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21, San Diego, CA, Poster No. A-475, 2015.